Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 5/20 | 0.43 |
| ▸ | CTSB | P07858 | 3/20 | 0.40 |
| ▸ | CTSS | P25774 | 3/20 | 0.40 |
| ▸ | CTSK | P43235 | 3/20 | 0.40 |
| ▸ | LNPEP | Q9UIQ6 | 5/20 | 0.40 |
| ▸ | ERAP2 | Q6P179 | 3/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.39 |
| ▸ | ERAP1 | Q9NZ08 | 2/20 | 0.38 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.37 |
| ▸ | HPGDS | O60760 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | KDR | P35968 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6984396 | 0.83 | CTSL (0.43) | CTSLCTSBCTSSCTSKLNPEP | |
| SCHEMBL6984404 | 0.81 | ITGB1 (0.40) | CTSLCTSBCTSSCTSKLNPEP | |
| SCHEMBL6747702 | 0.76 | CTSL (0.44) | CTSLCTSBCTSSCTSKL3MBTL1 | |
| SCHEMBL6747703 | 0.73 | CTSL (0.40) | CTSLCTSBCTSSCTSKL3MBTL1 | |
| SCHEMBL6988397 | 0.72 | CTSL (0.43) | CTSLCTSBCTSSCTSKLNPEP | |
| SCHEMBL6751806 | 0.71 | CTSL (0.54) | CTSLCTSBCTSSCTSKUSP30 | |
| SCHEMBL6751811 | 0.69 | CTSL (0.48) | CTSLCTSBCTSSCTSKUSP30 | |
| SCHEMBL4452807 | 0.68 | CTSS (0.57) | CTSLCTSSCTSK | |
| SCHEMBL6751681 | 0.68 | CTSK (0.44) | CTSLCTSBCTSSCTSKALDH1A1 | |
| SCHEMBL5926429 | 0.68 | HDAC1 (0.58) | LNPEPERAP2ERAP1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040127549-A1 | Cyclic 2-carbonylaminoketones as inhibitors of cruzipain and other cysteine proteases | AMURA THERAPEUTICS LIMITED (GB) | 2004-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127549-A1 | Cyclic 2-carbonylaminoketones as inhibitors of cruzipain and other cysteine proteases | CPN1, CTRL, CPA1 | CTSL 23/4885CTSB 85/4885CTSS 46/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.